Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Sound Pharmaceuticals completed this new Phase 2a study testing SPI-1005, an investigational drug that contains ebselen, as a new treatment for bipolar disorder.

Trees in the shape of two heads, one with green leaves in blue sky and the other with empty branches in grey sky.

Professor Phil Cowen, Department of Psychiatry, University of Oxford, said,

“This work was done in collaboration with colleagues from the Department of Pharmacology at the University of Oxford who discovered that a drug called ebselen had pharmacological properties similar to those of the mood-stabilising drug, lithium. Lithium is a very useful agent in bipolar disorder but is not well-tolerated and requires regular blood tests. Ebselen would be free from these problems.

"The study shows important preliminary evidence of therapeutic activity for SPI-1005 in bipolar disorder. This pilot investigation has given us critical information to inform design of future trials and has confirmed the safety of SPI-1005 in a group of patients with severe mental illness taking multiple medications.” 

The study was funded by the Stanley Medical Research Institute and the medication was supplied by Sound Pharmaceuticals.

To read the full press release

To read the full study, A phase 2a randomised, double-blind, plcebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Just Over Half of British Indians Would Get COVID Vaccine

COVID-19 Mental Health

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

Mental Health Schizophrenia

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental Mental Health Worse Since New National Restrictions

COVID-19 Child and adolescent Early intervention Mental Health Psychological therapy

Parental stress, depression, and anxiety have again increased since new national restrictions have been introduced according to the latest report from the Oxford University led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study based on data from over 6000 UK parents.

Potential New Target to Prevent or Delay Dementia

Alzheimer's disease Dementia Mental Health Old-age psychiatry

New study shows targeting arterial stiffening earlier in a person’s lifespan could provide cognitive benefits in older age and may help to delay the onset of dementia.

SSRI Treatment in Young People with Depression and Anxiety

Anxiety Depression Mental Health

Results from an insight review commissioned by the Wellcome Trust, highlights what is currently known about the benefits and risks of using selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression and anxiety in young people.

Collaborating with Youth is Key to Studying Mental Health Management

Anxiety Depression Mental Health

The Global Mental Health Databank, a feasibility study, hopes to enable youth from the United Kingdom, South Africa, and India to work directly with mental health researchers to better understand how young people can manage their own mental health.